Fig. S4. **Effect of AMD3100 on pathways.** BTRT cells grown in 3D Matrigel culture were treated with vehicle (V), AMD3100 (A; 10μM), trastuzumab (T; 20 μg/ml), or their combination (A+T). Cell lysates were subject to RPPA (Materials and Methods, Fig. 5A). A portion of the RPPA data were further analyzed with one-way ANOVA (mean ± SD; P value based on log2 data: $*P < 0.05$, $**P < 0.01$, $***P < 0.001$ compared with the vehicle; $\#P < 0.05$, $\#\#P < 0.01$, $\#\#\#P < 0.001$ compared with trastuzumab).